Should you buy Johnson & Johnson stock now?
The technical signal for Johnson & Johnson is currently Hold. Johnson & Johnson trades at $254.78 as of Oct 7, 2026. The technical analysis shows the following: MACD is negative (bearish trend) at -2.439 with falling momentum (signal: -0.308); RSI is at 33.6 (neutral zone); the stock is in a short-term downtrend (price below the 20-day average); the analyst price target of $279.27 points to 9.6% upside. This is a technical observation based on current data, not investment advice.
What is the price target for Johnson & Johnson stock?
The average analyst price target for Johnson & Johnson is $279.27. The current price is $254.78, which gives an upside of 9.6%. Based on this, the stock is considered fairly valued. The fair value range (±10% of the price target) is between $251.34 and $307.20.
Is Johnson & Johnson a dividend stock?
Yes, Johnson & Johnson is a dividend stock with a dividend yield of 1.93%. The latest dividend was $1.34 per share. The latest ex-dividend date (traded without the dividend) was Aug 25, 2026. The payout ratio is 48.6%, which is considered sustainable.
When does Johnson & Johnson pay a dividend in 2026?
The next dividend date for Johnson & Johnson has not been set yet. The latest ex-dividend date (last trading day with dividend rights) was Aug 25, 2026. The latest dividend was $1.34 per share with an ex-dividend date of Aug 25, 2026. The dividend yield is 1.93%. The payout ratio of 48.6% points to a sustainable dividend with room to grow.
What is the risk of Johnson & Johnson stock?
Johnson & Johnson is rated as a stock in the risk category Conservative. the annual standard deviation is 18.9%, which classifies the stock as Conservative.
Is Johnson & Johnson overvalued?
Johnson & Johnson is considered fairly valued – the price is close to the analyst price target. Johnson & Johnson has the following valuation ratios: a P/E ratio of 31.6 (highly valued), a P/S ratio of 6.6, a P/B ratio of 7.6. The stock trades close to the analyst price target and is considered fairly valued.
Is Johnson & Johnson overbought?
No, Johnson & Johnson is not overbought. RSI is at 33.6 (neutral zone). The technical indicators show: RSI is at 33.6 (neutral zone between 30-70), which signals neither overbought nor oversold. In addition, the price is 4.2% below the 20-day average (short-term downtrend). In addition, MACD is negative with falling momentum (bearish).
When is the next Johnson & Johnson earnings report?
Johnson & Johnson reports its next earnings on October 13, 2026. The stock currently trades at $254.78. With a P/E ratio of 31.6, the market will be watching closely whether earnings meet expectations. The RSI is at 33.6, so the report can reinforce the current technical trend.
Is Johnson & Johnson shorted?
Johnson & Johnson has minimal short interest of 0.98% of the free float, which is insignificant and points to very limited bearish sentiment.
Are insiders buying Johnson & Johnson stock?
No, insiders are not buying Johnson & Johnson shares – they are net sellers. Over the last 3 months, insiders have made 0 purchases and 6 sales. On a net basis, 55,214,471 $ worth of shares were sold. Across the last 20 reported transactions, the split is 1 purchases and 19 sales, with a net 97,284,410 $ sold. Active sellers include Schmid Timothy, Taubert Jennifer L, Duato Joaquin and others. Insider selling can have several explanations (e.g. planned 10b5-1 sales, portfolio diversification or taxes), but sustained selling by several insiders is worth watching closely.
Is Johnson & Johnson a good stock?
Based on our total score, Johnson & Johnson is rated as a good stock with a total score of 62 out of 100. The stock scores above average on value, quality and momentum. The score is made up of Value: 29/100, Quality: 87/100, Momentum: 72/100. In addition: a dividend of 1.93%; technical signal: Hold. Whether Johnson & Johnson is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for Johnson & Johnson stock?
The outlook for Johnson & Johnson based on current data: the average analyst price target is $279.27 (+9.6%); the next earnings report is due on Oct 13, 2026, which can move the price; the P/E ratio is 31.6 (high – the market expects growth). Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is Johnson & Johnson stock falling?
Johnson & Johnson is falling right now. The technical indicators show: the price is 4.2% below the 20-day average; MACD is negative with falling momentum (bearish signal); insiders have mostly been selling the stock recently. For the latest context, see our technical analysis and insider section above.
How high can Johnson & Johnson go?
The average analyst price target for Johnson & Johnson is $279.27, which corresponds to a potential gain of 9.6% from the current price of $254.78. The stock has traded between $178.89 and $281.07 over the last 52 weeks. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can Johnson & Johnson fall?
The stock has traded as low as $178.89 over the last 52 weeks — that is 29.8% below the current price of $254.78. The biggest decline (drawdown) in the same period was 36.4% from high to low. Within a year, the price typically swings about ±18.9% (standard deviation — a measure of price swings). A difficult year could therefore mean a further decline of that size. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does Johnson & Johnson do?
Johnson & Johnson is a large healthcare and medicine company. It makes money by developing, producing and selling medicines and consumer health products.
The company owns several well-known brands. For example, it sells skin care products under names like Neutrogena and Aveen... The company belongs to the Healthcare sector, more specifically the Drug Manufacturers - General industry, is headquartered in United States, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate Johnson & Johnson as an investment.
Did Johnson & Johnson raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from Johnson & Johnson. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history above.
Is Johnson & Johnson making money or losing money?
Yes, Johnson & Johnson is making money, not losing it. The company has a profit margin (the share of revenue left over as profit) of 21.5% — which is excellent. The operating margin (profit before interest and taxes) is 29.2%. At a P/E ratio of 31.6, you currently pay 31.6 dollars for every dollar of the company's annual earnings. A consistently profitable company is usually more resilient than growth stocks that are not yet making money.
Can Johnson & Johnson go bankrupt?
The bankruptcy risk of Johnson & Johnson is rated as low. Altman Z2 (a model for assessing financial distress) is 4.58 — that places the company in the healthy zone. The company has a healthy balance sheet with limited debt relative to earnings and assets. The Piotroski score (financial health 0-9, higher is better) is 8 — which is strong. Debt relative to equity is 152% (high). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does Johnson & Johnson have a lot of debt?
Yes, Johnson & Johnson has elevated debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 152%. For the healthcare sector, anything above 150% counts as elevated — that raises the financial risk, especially if interest rates rise or earnings fall. In healthcare, 80-150% is typical — large pharma companies carry debt for research and acquisitions. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector. Can Johnson & Johnson service its debt? Can service its debt without problems — the interest coverage ratio (how many times earnings can cover interest payments) is 25.0x, and net debt equals 0.8 years of earnings (EBITDA).
